These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 12686820)

  • 1. Transdermal estradiol therapy for advanced prostate cancer--forward to the past?
    Ockrim JL; Lalani EN; Laniado ME; Carter SS; Abel PD
    J Urol; 2003 May; 169(5):1735-7. PubMed ID: 12686820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma.
    Bland LB; Garzotto M; DeLoughery TG; Ryan CW; Schuff KG; Wersinger EM; Lemmon D; Beer TM
    Cancer; 2005 Feb; 103(4):717-23. PubMed ID: 15641029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy.
    Ockrim J; Lalani el-N; Abel P
    Nat Clin Pract Oncol; 2006 Oct; 3(10):552-63. PubMed ID: 17019433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit?
    Ockrim JL; Lalani el-N; Aslam M; Standfield N; Abel PD
    BJU Int; 2006 Mar; 97(3):498-504. PubMed ID: 16469015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal oestrogen therapy as a second-line hormonal intervention in prostate cancer: a bad experience.
    Kandola S; Anyamene N; Payne H; Harland S
    BJU Int; 2007 Jan; 99(1):53-5. PubMed ID: 17227492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lycopene for advanced hormone refractory prostate cancer: a prospective, open phase II pilot study.
    Schwenke C; Ubrig B; Thürmann P; Eggersmann C; Roth S
    J Urol; 2009 Mar; 181(3):1098-103. PubMed ID: 19150092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Langley RE; Gilbert DC; Duong T; Clarke NW; Nankivell M; Rosen SD; Mangar S; Macnair A; Sundaram SK; Laniado ME; Dixit S; Madaan S; Manetta C; Pope A; Scrase CD; Mckay S; Muazzam IA; Collins GN; Worlding J; Williams ST; Paez E; Robinson A; McFarlane J; Deighan JV; Marshall J; Forcat S; Weiss M; Kockelbergh R; Alhasso A; Kynaston H; Parmar M
    Lancet; 2021 Feb; 397(10274):581-591. PubMed ID: 33581820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.
    Baker VL
    Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
    BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of high dose oestrogen therapy on circulating inflammatory markers.
    Wilson R; Spiers A; Ewan J; Johnson P; Jenkins C; Carr S
    Maturitas; 2009 Mar; 62(3):281-6. PubMed ID: 19231116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.
    Serrano D; Mariani L; Mora S; Guerrieri-Gonzaga A; Cazzaniga M; Daldoss C; Ramazzotto F; Feroce I; Decensi A; Bonanni B
    Maturitas; 2006 Aug; 55(1):69-75. PubMed ID: 16500052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.
    Ockrim JL; Lalani el-N; Kakkar AK; Abel PD
    J Urol; 2005 Aug; 174(2):527-33; discussion 532-3. PubMed ID: 16006886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.